These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 1929250

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group.
    N Engl J Med; 2011 Feb 03; 364(5):422-31. PubMed ID: 21288078
    [Abstract] [Full Text] [Related]

  • 24. Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection.
    Chahine EB, Sucher AJ, Mantei K.
    Consult Pharm; 2014 Sep 03; 29(9):614-24. PubMed ID: 25203410
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
    Babakhani F, Gomez A, Robert N, Sears P.
    Antimicrob Agents Chemother; 2011 Sep 03; 55(9):4427-9. PubMed ID: 21709084
    [Abstract] [Full Text] [Related]

  • 28. Phenelfamycins, a novel complex of elfamycin-type antibiotics. III. Activity in vitro and in a hamster colitis model.
    Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NR, Coen LJ, Fernandes PB.
    J Antibiot (Tokyo); 1989 Jan 03; 42(1):94-101. PubMed ID: 2921230
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
    James GA, Chesnel L, Boegli L, deLancey Pulcini E, Fisher S, Stewart PS.
    J Antimicrob Chemother; 2018 Jan 01; 73(1):102-108. PubMed ID: 29029221
    [Abstract] [Full Text] [Related]

  • 34. In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.
    Weiss W, Pulse M, Vickers R.
    Antimicrob Agents Chemother; 2014 Oct 01; 58(10):5714-8. PubMed ID: 25022586
    [Abstract] [Full Text] [Related]

  • 35. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
    Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP.
    Antimicrob Agents Chemother; 2008 Mar 01; 52(3):1121-6. PubMed ID: 18195066
    [Abstract] [Full Text] [Related]

  • 36. Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype.
    Buckley AM, Spencer J, Maclellan LM, Candlish D, Irvine JJ, Douce GR.
    PLoS One; 2013 Mar 01; 8(5):e64121. PubMed ID: 23704976
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
    Chen C, Doll NK, Casadei G, Bremner JB, Lewis K, Kelso MJ.
    Bioorg Med Chem Lett; 2014 Jan 15; 24(2):595-600. PubMed ID: 24360560
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis.
    Borriello SP, Ketley JM, Mitchell TJ, Barclay FE, Welch AR, Price AB, Stephen J.
    J Med Microbiol; 1987 Aug 15; 24(1):53-64. PubMed ID: 3612744
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.